News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

|Articles|September 23, 2010

CN V3 Promotions - Register - display - Title

Thanks for registering!

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related Content

The addition of zovegalisib to fulvestrant led to rapid declines in PIK3CA and ESR1 ctDNA in the HR-positive/HER2-negative advanced breast cancer group.

Zovegalisib Combo Confers Efficacy Benefit in PIK3CA-Mutated Breast Cancer

ByRoman Fabbricatore

December 28th 2025

‘Relatively Low’ AEs Noted With Durvalumab/FLOT in Gastric/GEJ Cancer

ByYelena Y. Janjigian, MD

December 28th 2025

A Look Back on the Top 10 Oncology Interviews in 2025

ByAriana Pelosci

December 28th 2025

Durvalumab/FLOT Cemented as New SOC in Gastric/GEJ Cancers

ByYelena Y. Janjigian, MD

December 27th 2025

The Evolution of Distress Screening in Cancer Care

ByAriana Pelosci

December 27th 2025

Trending on CancerNetwork

Spotlighting the Top 10 FDA Oncology Approvals in 2025

Durvalumab/FLOT Cemented as New SOC in Gastric/GEJ Cancers

The Evolution of Distress Screening in Cancer Care

Why is Lymphedema Detected So Late in Breast Cancer?

A Look Back on the Top 10 Oncology Interviews in 2025